Neurodegenerative Disease Market Size, Scope, Forecast Report 2026 to 2035
Segmentation of Neurodegenerative Disease Market :
Neurodegenerative Disease Market, By Disease Indication-
- Alzheimer’s Disease
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington’s Disease
- Other Rare Neurodegenerative Disorders
Neurodegenerative Disease Market, By Drug Class / Mechanism of Action-
- Neuroinflammation & Microglia-Targeting Therapies
- CSF-1R inhibitors
- TREM2 / microglia modulators
- Anti-Amyloid Therapies
- Anti-Tau Therapies
- Dopaminergic Therapies
- Glutamate Modulators / Neuroprotective Agents
- Gene-Targeted & RNA-Based Therapies
- ASOs
- Gene therapies
- Symptomatic & Supportive Drug Therapies
Neurodegenerative Disease Market, By Modality-
- Small Molecules
- Biologics
- Gene Therapies
- RNA Therapeutics
- Combination Therapies
Neurodegenerative Disease Market, By Route of Administration-
- Oral
- Injectable (IV / SC / IM)
- Intrathecal / CNS-Directed Delivery
Neurodegenerative Disease Market, By Disease Stage-
- Early / Prodromal
- Moderate
- Advanced / Late Stage
Neurodegenerative Disease Market By Distribution Channel
- Hospital Pharmacy
- Specialty Pharmacy
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neurodegenerative Disease Market Snapshot
Chapter 4. Global Neurodegenerative Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Disease Indication Estimates & Trend Analysis
5.1. by Disease Indication & Market Share, 2025 & 2035
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Disease Indication:
5.2.1. Alzheimer’s Disease
5.2.2. Parkinson’s Disease
5.2.3. Amyotrophic Lateral Sclerosis (ALS)
5.2.4. Huntington’s Disease
5.2.5. Other Rare Neurodegenerative Disorders
Chapter 6. Market Segmentation 2: by Drug Class / Mechanism of Action Estimates & Trend Analysis
6.1. by Drug Class / Mechanism of Action & Market Share, 2025 & 2035
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Drug Class / Mechanism of Action:
6.2.1. Neuroinflammation & Microglia-Targeting Therapies
6.2.2. CSF-1R Inhibitors
6.2.3. TREM2 / Microglia Modulators
6.2.4. Anti-Amyloid Therapies
6.2.5. Anti-Tau Therapies
6.2.6. Dopaminergic Therapies
6.2.7. Glutamate Modulators / Neuroprotective Agents
6.2.8. Gene-Targeted & RNA-Based Therapies
6.2.9. Antisense Oligonucleotides (ASOs)
6.2.10. Gene Therapies
6.2.11. Symptomatic & Supportive Drug Therapies
Chapter 7. Market Segmentation 3: by Modality Estimates & Trend Analysis
7.1. by Modality & Market Share, 2025 & 2035
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Modality:
7.2.1. Small Molecules
7.2.2. Biologics
7.2.3. Gene Therapies
7.2.4. RNA Therapeutics
7.2.5. Combination Therapies
Chapter 8. Market Segmentation 4: by Route of Administration Estimates & Trend Analysis
8.1. by Route of Administration & Market Share, 2025 & 2035
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Route of Administration:
8.2.1. Oral
8.2.2. Injectable (IV / SC / IM)
8.2.3. Intrathecal / CNS-Directed Delivery
Chapter 9. Market Segmentation 5: by Disease Stage Estimates & Trend Analysis
9.1. by Disease Stage & Market Share, 2025 & 2035
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Disease Stage:
9.2.1. Early / Prodromal
9.2.2. Moderate
9.2.3. Advanced / Late Stage
Chapter 10. Market Segmentation 6: by Distribution Channel Estimates & Trend Analysis
10.1. by Distribution Channel & Market Share, 2025 & 2035
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Distribution Channel:
10.2.1. Hospital Pharmacy
10.2.2. Specialty Pharmacy
Chapter 11. Neurodegenerative Disease Market Segmentation: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2035
11.1.2. North America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Drug Class / Mechanism of Action, 2022-2035
11.1.3. North America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2022-2035
11.1.4. North America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
11.1.5. North America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Stage, 2022-2035
11.1.6. North America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2035
11.1.7. North America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
11.2. Europe
11.2.1. Europe Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2035
11.2.2. Europe Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Drug Class / Mechanism of Action, 2022-2035
11.2.3. Europe Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2022-2035
11.2.4. Europe Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
11.2.5. Europe Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Stage, 2022-2035
11.2.6. Europe Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2035
11.2.7. Europe Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
11.3. Asia Pacific
11.3.1. Asia Pacific Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2035
11.3.2. Asia Pacific Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Drug Class / Mechanism of Action, 2022-2035
11.3.3. Asia Pacific Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2022-2035
11.3.4. Asia Pacific Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
11.3.5. Asia Pacific Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Stage, 2022-2035
11.3.6. Asia Pacific Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2035
11.3.7. Asia Pacific Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
11.4. Latin America
11.4.1. Latin America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2035
11.4.2. Latin America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Drug Class / Mechanism of Action, 2022-2035
11.4.3. Latin America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2022-2035
11.4.4. Latin America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
11.4.5. Latin America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Stage, 2022-2035
11.4.6. Latin America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2035
11.4.7. Latin America Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
11.5. Middle East & Africa
11.5.1. Middle East & Africa Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2035
11.5.2. Middle East & Africa Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Drug Class / Mechanism of Action, 2022-2035
11.5.3. Middle East & Africa Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2022-2035
11.5.4. Middle East & Africa Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
11.5.5. Middle East & Africa Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Stage, 2022-2035
11.5.6. Middle East & Africa Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2035
11.5.7. Middle East & Africa Neurodegenerative Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Biogen Inc.
12.2.2. Pfizer, Inc.
12.2.3. Hoffmann-La Roche Ltd.
12.2.4. Merck & Co., Inc.
12.2.5. Novartis AG
12.2.6. Sanofi
12.2.7. Teva Pharmaceutical Industries Ltd.
12.2.8. UCB S.A.
12.2.9. ACADIA Pharmaceuticals Inc.
12.2.10. H. Lundbeck A/S
12.2.11. Mitsubishi Tanabe Pharma Corporation
12.2.12. Alector Therapeutics
12.2.13. Denali Therapeutics
12.2.14. Prothena
12.2.15. AC Immune
12.2.16. Annovis Bio
12.2.17. ProMIS Neurosciences
12.2.18. Arrowhead Pharmaceuticals
12.2.19. Cerevance
12.2.20. Neurizon Therapeutics
12.2.21. SciNeuro Pharmaceuticals
12.2.22. Origami Therapeutics
12.2.23. Muna Therapeutics
12.2.24. Neuraly
12.2.25. PharmaKure
12.2.26. Nitrase Therapeutics
12.2.27. Prevail Therapeutics
12.2.28. Shape Therapeutics
12.2.29. Ophidion, Inc.
12.2.30. ImStar Therapeutics
12.2.31. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Neurodegenerative Disease Market Size is valued at USD 45.89 Billion in 2025 and is predicted to reach USD 78.75 Billion by the year 2035
Neurodegenerative Disease Market is expected to grow at a 5.80% CAGR during the forecast period for 2026 to 2035.
Biogen Inc., Pfizer, Inc., Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., UCB S.A., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, Alector Therapeutics, Denali Therapeutics, Prothena and Others.
Neurodegenerative Disease Market is segmented in Drug Class (NMDA, SSRIs, Decarboxylase inhibitors, Cholinesterase Inhibitors, Immunomodulators, Dopamine Inhibitors), By Applications and Other.
North America region is leading the Neurodegenerative Disease Market .